We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW (LifeSkills)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05018611
Recruitment Status : Recruiting
First Posted : August 24, 2021
Last Update Posted : July 26, 2022
Sponsor:
Collaborators:
Children's Hospital Los Angeles
Ann & Robert H Lurie Children's Hospital of Chicago
Information provided by (Responsible Party):
Matthew Mimiaga, ScD, MPH, MA, University of California, Los Angeles

Brief Summary:
The LifeSkills Mobile app will be evaluated in a randomized controlled trial (RCT) among 5,000 young transgender women (YTW), ages 16-29 in the United States (U.S.). Study findings will demonstrate if the intervention will reduce HIV incidence.

Condition or disease Intervention/treatment Phase
HIV Prevention Behavioral: LifeSkills Mobile Not Applicable

Detailed Description:
LifeSkills Mobile is an mHealth intervention to promote biobehavioral HIV prevention strategies based on empowerment theory and was developed using a community-based participatory research approach. An RCT assesses the efficacy of the LifeSkills Mobile intervention in comparison to a standard of care (SOC) condition among 5,000 YTW recruited online. At baseline and every 6 months through 12-48 months (depending on when the participant enrolled), enrolled participants will complete an online survey sent via a link to their mobile phone and will be mailed an OraQuick In-Home HIV Test kit. We will also estimate the total and incremental costs of the LifeSkills Mobile intervention relative to SOC, from healthcare sector and societal perspectives.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Digital, Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in Young Transgender Women
Actual Study Start Date : December 6, 2021
Estimated Primary Completion Date : February 28, 2026
Estimated Study Completion Date : February 28, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: LifeSkills Mobile
Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
Behavioral: LifeSkills Mobile
A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.

No Intervention: Standard of Care
HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.



Primary Outcome Measures :
  1. HIV incidence [ Time Frame: 12-48 months post-baseline (depending on when participants enroll in the study) ]
    Participants will be mailed and take an OraQuick In-Home HIV Test. Reactive HIV screening tests will be confirmed via dried blood spot (DBS; detectable antibodies). The main analysis will assess whether there are differences in survival (or cumulative incidence of HIV) among those randomized to LifeSkills Mobile versus those randomized to SOC.


Secondary Outcome Measures :
  1. Changes in sexual risk behavior at 6 months based on self-report [ Time Frame: 6 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  2. Changes in sexual risk behavior at 12 months based on self-report [ Time Frame: 12 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  3. Changes in sexual risk behavior at 18 months based on self-report [ Time Frame: 18 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  4. Changes in sexual risk behavior at 24 months based on self-report [ Time Frame: 24 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  5. Changes in sexual risk behavior at 30 months based on self-report [ Time Frame: 30 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  6. Changes in sexual risk behavior at 36 months based on self-report [ Time Frame: 36 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  7. Changes in sexual risk behavior at 42 months based on self-report [ Time Frame: 42 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  8. Changes in sexual risk behavior at 48 months based on self-report [ Time Frame: 48 months post-baseline ]
    Self-reported total condomless anal or vaginal sex acts in the prior 30 days without protection via PrEP

  9. Comparison of costs between LifeSkills Mobile intervention vs SOC [ Time Frame: End of study ]
    Total and incremental costs of the LifeSkills Mobile intervention relative to SOC, from healthcare sector and societal perspectives

  10. PrEP outcomes (linkage, initiation, retention) [ Time Frame: 12-48 months post-baseline (depending on when participants enroll in the study) ]
    PrEP care linkage defined as attending at least one PrEP-related care visit to assess medical eligibility for PrEP initiation in the prior 6 months, per self-report PrEP initiation defined as starting PrEP medication in the prior 6-month period by self-report PrEP retention defined as: at least one PrEP care visit in a 6-month period PrEP visit constancy defined as at least one visit every six months over a 12-month period per self-report



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 29 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Self-identified as transgender, woman, and/or along the feminine spectrum
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Self-identified as transgender, woman, and/or along the feminine spectrum with a male assigned sex at birth
  • Ages 16-29
  • HIV uninfected at enrollment visit, verified via HIV home test kit
  • Self-reported lifetime history of condomless sex or recent history of sex (anal or vaginal in the past 12 months)
  • Able to speak/understand English
  • Owns a smartphone or home computer or willing to use one in the study
  • Willing and able to provide informed consent/assent

Exclusion Criteria:

  • Unable to provide informed consent due to severe mental or physical illness, or substance intoxication at time of enrollment
  • Discovery of active suicidal ideation or major mental illness (e.g. untreated psychosis or mania) at the time of the interview (these patients will be referred immediately for treatment, but may join the study when this is resolved)
  • A positive Home HIV test kit result at baseline; these individuals will be immediately linked to HIV clinical care in their local areas.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05018611


Contacts
Layout table for location contacts
Contact: Matthew J Mimiaga, ScD, MPH 617-901-9276 mmimiaga@ph.ucla.edu
Contact: Lisa Kuhns, PhD, MPH 312-227-6119 LKuhns@luriechildrens.org

Locations
Layout table for location information
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Contact: Matthew J Mimiaga, ScD, MPH, MA       mmimiaga@ph.ucla.edu   
Sponsors and Collaborators
University of California, Los Angeles
Children's Hospital Los Angeles
Ann & Robert H Lurie Children's Hospital of Chicago
Investigators
Layout table for investigator information
Principal Investigator: Marvin Belzer, MD Children's Hospital Los Angeles
Principal Investigator: Matthew J Mimiaga, ScD, MD University of California, Los Angeles
Principal Investigator: Lisa Kuhns, PhD, MPH Ann & Robert H Lurie Children's Hospital of Chicago
Layout table for additonal information
Responsible Party: Matthew Mimiaga, ScD, MPH, MA, Professor of Epidemiology, UCLA Fielding School of Public Health, and Psychiatry & Biobehavioral Sciences, UCLA David Geffen School of Medicine, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT05018611    
Other Study ID Numbers: 1 U01 A1156875
First Posted: August 24, 2021    Key Record Dates
Last Update Posted: July 26, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Matthew Mimiaga, ScD, MPH, MA, University of California, Los Angeles:
Transgender women (TGW)
PrEP
mHealth
HIV Prevention
Sexual Behavior